The shares have slumped 28% this year. Savara said the agency told it that it would miss the target action date of Sunday, Nov. 22, for the biologics license application.
The FDA review is continuing, and the agency has not provided a revised action date, according to Savara.
Comments (0)
No comments yet. Be the first!